About Monovisc

Monovisc was developed by Anika Therapeutics, a leader in hyaluronic acid-based therapies. Approved by the FDA in 2013, Monovisc was created as a single-injection treatment for knee osteoarthritis. The product was designed to deliver long-lasting relief and improve joint function, offering an effective, minimally invasive alternative to surgery.

How It Works?

Monovisc contains hyaluronic acid, which restores the joint’s natural fluid, reducing friction, pain, and inflammation. This provides immediate relief, enhances joint mobility, and improves comfort. Its unique formula requires only one injection, offering lasting pain relief for up to 6 months, making it a convenient and effective non-surgical solution for OA symptoms.

Key Features

Easy single-injection treatment.
Relief that lasts for 26 weeks.
Highly concentrated HA derived from non-animal sources.
One injection is more convenient than several doctor appointments.
There have been no documented, proven pseudo septic responses.

Results

Immediate: Extra lubrication reduces friction and discomfort.
After 1 to 2 Weeks: Continued pain relief and reduced inflammation help improve joint function.
After 4 to 6 Weeks: Significant pain reduction and enhanced joint mobility, lasting up to 6 months.